v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table

The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the CHC Committee views the link between the Company’s performance and its NEOs’ pay. For a discussion of how the Company views its executive compensation structure, including alignment with Company performance, see the Compensation Discussion and Analysis (“CD&A”) beginning on page 48. The CHC Committee did not consider the pay versus performance disclosure below in making its pay decisions.

In accordance with SEC rules, the following table sets forth information concerning compensation actually paid (“CAP”). The disclosure and calculation of CAP is required by the SEC’s rules. Neither CAP nor the amount reported in the Summary Compensation Table (“SCT”) reflects the amount of compensation actually paid, earned, or received during the applicable year. Per SEC rules, CAP was calculated by adjusting SCT total values for the applicable year as described in the footnotes to the following table.

 

 

SCT Total

 

 

 

 

 

 

Average
SCT Total

 

 

 

 

 

 

Value of Initial $100
Investment Based On:(4)

 

 

 

 

 

 

Adjusted
Operating

Year(1)

 

Pay for
CEO(2)

 

CAP to
CEO(3)

 

Pay for
Other NEOs(2)

 

Avg. CAP
to Other NEOs(3)

 

Company
TSR

 

Peer Group
TSR

 

Net Income
($ Millions)(5)

 

Income
($ Millions)(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

 

$

18,339,913

 

 

 

 

$

30,129,512

 

 

 

 

$

4,218,554

 

 

 

 

$

5,988,288

 

 

 

 

$

150

 

 

 

 

$

148

 

 

 

 

$

877

 

 

 

 

$

2,002

 

 

2024

 

 

$

19,327,354

 

 

 

 

$

21,331,191

 

 

 

 

$

3,720,781

 

 

 

 

$

3,939,467

 

 

 

 

$

163

 

 

 

 

$

147

 

 

 

 

$

746

 

 

 

 

$

1,797

 

 

2023

 

 

$

15,979,355

 

 

 

 

$

23,757,594

 

 

 

 

$

4,130,301

 

 

 

 

$

4,760,148

 

 

 

 

$

160

 

 

 

 

$

143

 

 

 

 

$

418

 

 

 

 

$

1,188

 

 

2022

 

 

$

14,927,297

 

 

 

 

$

(2,318,591

)

 

 

 

$

4,387,737

 

 

 

 

$

788,126

 

 

 

 

$

140

 

 

 

 

$

140

 

 

 

 

$

1,279

 

 

 

 

$

2,550

 

 

2021

 

 

$

20,551,605

 

 

 

 

$

49,697,101

 

 

 

 

$

4,710,348

 

 

 

 

$

11,665,084

 

 

 

 

$

186

 

 

 

 

$

143

 

 

 

 

$

2,377

 

 

 

 

$

3,830

 

 

 

(1)
For each year shown, the CEO was Adam H. Schechter and the other NEOs were as follows for each fiscal year:
•
2025: Megan D. Bailey, Brian J. Caveney, Mark S. Schroeder, and Julia A. Wang
•
2024: Glenn A. Eisenberg, Brian J. Caveney, Anita Z. Graham, Mark S.Schroeder, and Julia A. Wang
•
2023: Glenn A. Eisenberg, Brian J. Caveney, Anita Z. Graham, Mark S. Schroeder, Paul R. Kirchgraber, and Thomas H. Pike
•
2021-2022: Glenn A. Eisenberg, Brian J. Caveney, Mark S. Schroeder, and Paul R. Kirchgraber
(2)
These amounts reflect (i) the total compensation reported in the SCT for the applicable year in the case of our CEO; and (ii) the average of the total compensation reported in the SCT for the applicable year for our Other NEOs. See the footnotes to the SCT for further detail regarding the amounts in this column for 2025, 2024, 2023, 2022, and 2021.
(3)
Amounts reported in these columns represent CAP; adjustments were made to the amounts reported in the SCT for the applicable year. A reconciliation of the adjustments for our CEO and for the average of the Other NEOs is set forth in the following tables, which describe the adjustments, each of which is prescribed by SEC rules to calculate the CAP amounts from SCT amounts. The fair value of options was determined by using the Black-Scholes option pricing method. The fair value of the performance share units was determined by using a Monte Carlo simulation pricing model and the probable outcome of the performance vesting conditions as of each measurement date and Company actual performance payouts for each completed performance period for the respective fiscal year. The fair value of the restricted stock units was determined using the stock price on the appropriate measurement date.
(4)
Reflects the cumulative TSR for the Company and the S&P 500 Health Care Index, which is the same industry index included in Part II, Item 5, “Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities,” furnished on page 37 of the 2025 Annual Report, assuming an initial investment of $100 on December 31, 2020. All dollar values assume reinvestment of all dividends, where applicable.
(5)
“Net income” is equivalent to “Net earnings” as reported in the Company’s financial statements.
(6)
SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (other than total shareholder return, stock price, or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected adjusted operating income as this measure for 2025, as reflected in the table above. Adjusted operating income is a non-GAAP measure. See reconciliation of adjusted operating income and operating income on page 94 of this Proxy Statement. This performance measure may not have been the most important financial performance measure for year 2021 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
       
Company Selected Measure Name Adjusted operating income        
Named Executive Officers, Footnote
(1)
For each year shown, the CEO was Adam H. Schechter and the other NEOs were as follows for each fiscal year:
•
2025: Megan D. Bailey, Brian J. Caveney, Mark S. Schroeder, and Julia A. Wang
•
2024: Glenn A. Eisenberg, Brian J. Caveney, Anita Z. Graham, Mark S.Schroeder, and Julia A. Wang
•
2023: Glenn A. Eisenberg, Brian J. Caveney, Anita Z. Graham, Mark S. Schroeder, Paul R. Kirchgraber, and Thomas H. Pike
•
2021-2022: Glenn A. Eisenberg, Brian J. Caveney, Mark S. Schroeder, and Paul R. Kirchgraber
       
Peer Group Issuers, Footnote
(4)
Reflects the cumulative TSR for the Company and the S&P 500 Health Care Index, which is the same industry index included in Part II, Item 5, “Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities,” furnished on page 37 of the 2025 Annual Report, assuming an initial investment of $100 on December 31, 2020. All dollar values assume reinvestment of all dividends, where applicable.
       
PEO Total Compensation Amount $ 18,339,913 $ 19,327,354 $ 15,979,355 $ 14,927,297 $ 20,551,605
PEO Actually Paid Compensation Amount $ 30,129,512 21,331,191 23,757,594 (2,318,591) 49,697,101
Adjustment To PEO Compensation, Footnote

Year

SCT Total
for CEO

Minus
Stock Award
Value &
Option
Award Value
Reported in
SCT for the
Covered Year

Plus
Year End
Fair Value of
Equity
Awards
Granted
During the
Covered Year
that Remain
Outstanding
and Unvested
as of Last
Day of the
Covered Year

Plus
Year over
Year Change
in Fair Value
as of the
Last Day of
the Covered
Year of
Outstanding
and
Unvested
Equity
Awards
Granted in
Prior Years

Plus
Year over
Year Change
in Fair Value
as of the
Vesting
Date of
Equity
Awards
Granted in
Prior Years
that Vested
During the
Covered Year

 

Minus
Fair Value
at the
End of the
Prior
Year of
Equity
Awards
that Failed
to Meet
Vesting
Conditions
in the
Covered Year

Plus
Value of
Dividends
or Other
Earnings Paid
on Stock or
Option Awards
Not Otherwise
Reflected in
Fair Value
or Total
Compensation
for the
Covered Year

Minus
Change in
Pension
Value
Reported in
SCT for
Covered Year

Plus
Pension
Adjustment

 

CEO CAP

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

$

18,339,913

 

 

 

$

14,155,045

 

 

 

$

18,955,605

 

 

 

$

6,008,578

 

 

 

$

597,331

 

 

 

$

-

 

 

 

$

383,130

 

 

$

-

 

 

$

-

 

 

 

$

30,129,512

 

2024

 

$

19,327,354

 

 

 

$

15,178,236

 

 

 

$

19,265,498

 

 

 

$

(1,526,430

)

 

 

$

(899,392

)

 

 

$

-

 

 

 

$

342,397

 

 

$

-

 

 

$

-

 

 

 

$

21,331,191

 

2023

 

$

15,979,355

 

 

 

$

11,321,392

 

 

 

$

16,874,513

 

 

 

$

2,589,227

 

 

 

$

(510,382

)

 

 

$

-

 

 

 

$

146,273

 

 

$

-

 

 

$

-

 

 

 

$

23,757,594

 

2022

 

$

14,927,297

 

 

 

$

11,205,369

 

 

 

$

9,883,707

 

 

 

$

(12,637,167

)

 

 

$

(3,304,274

)

 

 

$

-

 

 

 

$

17,215

 

 

$

-

 

 

$

-

 

 

 

$

(2,318,591

)

2021

 

$

20,551,605

 

 

 

$

15,040,149

 

 

 

$

26,465,842

 

 

 

$

15,202,072

 

 

 

$

2,517,731

 

 

 

$

-

 

 

 

 

-

 

 

$

-

 

 

$

-

 

 

 

$

49,697,101

 
       
Non-PEO NEO Average Total Compensation Amount $ 4,218,554 3,720,781 4,130,301 4,387,737 4,710,348
Non-PEO NEO Average Compensation Actually Paid Amount $ 5,988,288 3,939,467 4,760,148 788,126 11,665,084
Adjustment to Non-PEO NEO Compensation Footnote

Year

SCT
Average
for Other
NEOs

Minus
Stock Award
Value &
Option
Award Value
Reported in
SCT for the
Covered Year

Plus
Year End
Fair Value of
Equity
Awards
Granted
During the
Covered Year
that Remain
Outstanding
and Unvested
as of Last
Day of the
Covered Year

Plus
Year over
Year Change
in Fair Value
as of the
Last Day of
the Covered
Year of
Outstanding
and
Unvested
Equity
Awards
Granted in
Prior Years

Plus
Fair Value
as of
Vesting
Date of
Equity
Awards
Granted
and Vested
During the
Covered Year

Plus
Year over
Year Change
in Fair Value
as of the
Vesting
Date of
Equity
Awards
Granted in
Prior Years
that Vested
During the
Covered Year

Minus
Fair Value
at the
End of the
Prior
Year of
Equity
Awards that
Failed to
Meet Vesting
Conditions
in the
Covered Year

Plus
Value of
Dividends
or Other
Earnings Paid
on Stock or
Option Awards
Not Otherwise
Reflected in
Fair Value
or Total
Compensation
for the
Covered Year

Minus
Change in
Pension
Value
Reported in
SCT for
Covered Year

Plus
Pension
Adjustment

 

Average
Other
NEO CAP

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

$

4,218,554

 

 

 

$

2,720,064

 

 

 

$

3,641,617

 

 

 

$

730,493

 

 

 

$

-

 

 

 

$

63,220

 

 

 

$

-

 

 

 

$

57,265

 

 

 

$

2,797

 

 

$

-

 

 

 

$

5,988,288

 

2024

 

$

3,720,781

 

 

 

$

2,502,561

 

 

 

$

3,102,082

 

 

 

$

(216,915

)

 

 

$

-

 

 

 

$

(210,351

)

 

 

$

-

 

 

 

$

46,486

 

 

 

$

56

 

 

$

-

 

 

 

$

3,939,467

 

2023

 

$

4,130,301

 

 

 

$

2,503,265

 

 

 

$

3,011,920

 

 

 

$

244,996

 

 

 

$

22,107

 

 

 

$

(131,332

)

 

 

$

34,824

 

 

 

$

22,548

 

 

 

$

2,303

 

 

$

-

 

 

 

$

4,760,148

 

2022

 

$

4,387,737

 

 

 

$

3,185,873

 

 

 

$

2,991,119

 

 

 

$

(2,386,168

)

 

 

$

-

 

 

 

$

(1,023,666

)

 

 

$

-

 

 

 

$

4,977

 

 

 

$

-

 

 

$

-

 

 

 

$

788,126

 

2021

 

$

4,710,348

 

 

 

$

2,838,289

 

 

 

$

4,993,869

 

 

 

$

4,115,799

 

 

 

$

-

 

 

 

$

683,357

 

 

 

$

-

 

 

 

$

-

 

 

 

$

-

 

 

$

-

 

 

 

$

11,665,084

 
       
Compensation Actually Paid vs. Total Shareholder Return

Relationship of CAP vs. TSR (2021 – 2025)

The following chart sets forth the relationship between CAP to our CEO, average CAP to our other NEOs, the Company’s cumulative TSR over the five most recently completed fiscal years, and the cumulative TSR for the S&P 500 Health Care Index, which is the same industry index included in Part II, Item 5, “Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities,” furnished on page 37 of our 2025 Annual Report. Notwithstanding the use of the S&P 500 Health Care Index in this section, for our LTI plans, the Company’s TSR performance is measured against the peer group disclosed on page 55 of the CD&A, which we believe has a correlation between realized executive pay and performance.

 

img258147145_335.gif

        
Compensation Actually Paid vs. Net Income

Relationship of CAP vs. Net Income (2021 – 2025)

The following chart sets forth the relationship between CAP to our CEO, average CAP to our other NEOs, and the Company’s net income during the five most recently completed fiscal years.

 

img258147145_336.gif

        
Compensation Actually Paid vs. Company Selected Measure

Relationship of CAP vs. Adjusted Operating Income (2021 – 2025)

The following chart sets forth the relationship between CAP to our CEO, average CAP to our other NEOs, and the Company’s adjusted operating income during the five most recently completed fiscal years. See reconciliation of adjusted operating income and operating income on page 94 of this Proxy Statement.

 

img258147145_337.gif

        
Total Shareholder Return Vs Peer Group

Relationship of CAP vs. TSR (2021 – 2025)

The following chart sets forth the relationship between CAP to our CEO, average CAP to our other NEOs, the Company’s cumulative TSR over the five most recently completed fiscal years, and the cumulative TSR for the S&P 500 Health Care Index, which is the same industry index included in Part II, Item 5, “Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities,” furnished on page 37 of our 2025 Annual Report. Notwithstanding the use of the S&P 500 Health Care Index in this section, for our LTI plans, the Company’s TSR performance is measured against the peer group disclosed on page 55 of the CD&A, which we believe has a correlation between realized executive pay and performance.

 

img258147145_335.gif

        
Tabular List, Table

Financial Performance Measures

The most important financial performance measures used by the Company in setting pay-for-performance compensation for the most recently completed fiscal year are described in the table below. The manner in which these measures, together with certain non-financial performance measures, determine the amounts of incentive compensation of our NEOs is described above in the CD&A section. The order of the measures in this chart should not be interpreted as a ranking and are listed alphabetically.

 

Measure

 

 

Adjusted EPS

 

 

Adjusted Operating Income

 

 

Revenue

 

 

Relative Total Shareholder Return

 

 
       
Total Shareholder Return Amount $ 150 163 160 140 186
Peer Group Total Shareholder Return Amount 148 147 143 140 143
Net Income (Loss) $ 877,000,000 $ 746,000,000 $ 418,000,000 $ 1,279,000,000 $ 2,377,000,000
Company Selected Measure Amount 2,002,000,000 1,797,000,000 1,188,000,000 2,550,000,000 3,830,000,000
PEO Name Adam H. Schechter        
Measure:: 1          
Pay vs Performance Disclosure          
Name Adjusted EPS        
Measure:: 2          
Pay vs Performance Disclosure          
Name Adjusted Operating Income        
Non-GAAP Measure Description
(6)
SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (other than total shareholder return, stock price, or net income) used by the Company to link the CAP of our NEOs, for the most recently completed fiscal year, to our performance. We selected adjusted operating income as this measure for 2025, as reflected in the table above. Adjusted operating income is a non-GAAP measure. See reconciliation of adjusted operating income and operating income on page 94 of this Proxy Statement. This performance measure may not have been the most important financial performance measure for year 2021 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
       
Measure:: 3          
Pay vs Performance Disclosure          
Name Revenue        
Measure:: 4          
Pay vs Performance Disclosure          
Name Relative Total Shareholder Return        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (14,155,045) $ (15,178,236) $ (11,321,392) $ (11,205,369) $ (15,040,149)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 18,955,605 19,265,498 16,874,513 9,883,707 26,465,842
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 6,008,578 (1,526,430) 2,589,227 (12,637,167) 15,202,072
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 597,331 (899,392) (510,382) (3,304,274) 2,517,731
PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 383,130 342,397 146,273 17,215  
Non-PEO NEO | Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,797) (56) (2,303)    
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,720,064) (2,502,561) (2,503,265) (3,185,873) (2,838,289)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 3,641,617 3,102,082 3,011,920 2,991,119 4,993,869
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 730,493 (216,915) 244,996 (2,386,168) 4,115,799
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount     22,107    
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 63,220 (210,351) (131,332) (1,023,666) $ 683,357
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount     (34,824)    
Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 57,265 $ 46,486 $ 22,548 $ 4,977